Insight
How pharma companies can remain compliant with federal regulations around GP and customer services agreements
List prices for pharmaceuticals are in the crosshairs of regulators and consumer advocates. Yet lurking beneath the fray is another risk—namely, whether service agreements drug manufacturers make with their customers are appropriately excluded from their drug pricing calculations. KPMG can help pharmaceutical companies keep these service agreements in line with regulatory guidelines to avoid violating government pricing (GP) policy.
List prices for pharmaceuticals are in the crosshairs of regulators and consumer advocates.
